INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

Wall Street analysts forecast INM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

InMed Pharmaceuticals Inc revenue for the last quarter amounts to 1.12M USD, decreased -11.43 % YoY.

InMed Pharmaceuticals Inc. EPS for the last quarter amounts to -0.44 USD, decreased -99.19 % YoY.

InMed Pharmaceuticals Inc (INM) has 13 emplpoyees as of January 07 2026.

Today INM has the market capitalization of 3.17M USD.